Highlights From the ISTH 2021 Congress
Evolution of AAV Vector Gene Therapy Is Ongoing in Hemophilia. Will the Unique Features of BAY 2599023 Address the Outstanding Needs?
S.W. Pipe1, C. Hay2, J. Sheehan3, T. Lissitchkov4, M. Coppens5, H. Eichler6, S. Weigmann7, F. Ferrante8
1University of Michigan, Ann Arbor, United States
2Manchester University Dept. of Haematology, Manchester, United Kingdom
3University of Wisconsin–Madison, Madison, United States
4National Specialized Hospital for Active Treatment of Haematologic Diseases, Sofia, Bulgaria
5Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
6Institute of Clinical Haemostaseology and Transfusion Medicine, Saarland University, Homburg, Germany
7Bayer, Wuppertal, Germany
8Bayer, Basel, Switzerland
RELATED CONTENT
Interactive Webinars
Long-term Outcomes: Durability and Safety
Presented by Prof. Margareth C. Ozelo, MD, PhD...
Obstacles and Opportunities
Presented by Frank W.G. Leebeek, MD, PhD...
Patient Support, Patient Counseling, and Monitoring
Presented by Lindsey A. George, MD...
Gene Therapy for FVIII
Presented by K. John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPC...
Update on Efficacy of Clinical Trials
Presented by Guy Young, MD...
Adeno-Associated Viral (AAV) Vector Gene Therapy: Application to Hemophilia
Presented by Barbara A. Konkle, MD...
Gene Therapy for Treatment of Hemophilia: An Introduction to Adeno-Associated Viral Vector Gene Transfer
Presented by Johnny Mahlangu, BSc, MBBCh, MMed, FCPath...
Gene Therapy for Treatment of Hemophilia: Common Concerns in Gene Therapy
Presented by Thierry VandenDriessche, PhD...
Gene Therapy for Treatment of Hemophilia: Other Strategies and Targets
Presented by Glenn F. Pierce, MD, PhD...
A History of Hemophilia Treatment: Non-replacement Therapy to Gene Therapy
Presented by Steven W. Pipe, MD...
Getting to Know Gene Therapy: Terminology and Concepts
Presented by David Lillicrap, MD...
Podcasts